
    
      This is a Phase 1, randomized, open-label, single center, three period crossover study to
      determine the oral bioavailability of a new ABT-263 formulation relative to that of the
      current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately
      12 healthy female subjects will be enrolled in this study.
    
  